Targeted Treatment for Recurrent or Progressive Lung Cancer
Name of the Trial
Why Is This Trial Important?
In this clinical trial, researchers are testing a new drug called sorafenib to see if it can cause tumors to shrink or disappear in patients with metastatic non-small-cell lung cancer (NSCLC) that has recurred or progressed after previous treatment with chemotherapy. Sorafenib inhibits a protein called Raf kinase, which helps promote cell proliferation. Blocking Raf kinase activity may halt the spread of cancer cells.
Sorafenib also inhibits two other proteins named vascular endothelial growth factor receptors 2 and 3 (VEGFR2 and VEGFR3), which help tumors form new blood vessels (a process called angiogenesis). By blocking VEGFR2 and VEGFR3 activity, sorafenib may help cut off the blood supply to tumors and cause them to die.
"Sorafenib is a molecularly targeted oral medication with both antiproliferative and antiangiogenic properties," said Dr. Gutierrez. "It has shown some promising results against NSCLC in an earlier phase I study, and it appears to be well-tolerated. Most of the toxicity that we have seen has been mild and easy to control."
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.